Status:
WITHDRAWN
Markers for Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
AstraZeneca
Conditions:
Healthy Non-smokers
Current Smokers
Eligibility:
All Genders
30-75 years
Brief Summary
The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and ...
Eligibility Criteria
Inclusion
- Healthy non-smokers
- FEV1 \>80% predicted
- FEV1 reversibility of \<10% after inhaled (beta2-agonists
- Current smokers
- FEV1 no less than 80% predicted
- FEV1 reversibility of \<10% after inhaled (beta2-agonists
- Smoking history of \> 10 pack-years
- Moderate COPD
- FEV1 40-59% predicted
- FEV1 reversibility of \<10% after inhaled (beta2-agonists
- Smoking history of \> 10 pack-years\*\*
- Severe COPD
- FEV1 \<40% predicted
- FEV1 reversibility of \<10% after inhaled (beta2-agonists
- Smoking history of \> 10 pack-years
Exclusion
- FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists
- Asthma
- unstable disease (FEV1 \<35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.
Key Trial Info
Start Date :
July 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2002
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00180622
Start Date
July 1 2001
End Date
July 1 2002
Last Update
July 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY